AVIR
Atea Pharmaceuticals, Inc.NASDAQHealthcare$5.76+1.95%ClosedMarket Cap: $458.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.67
P/S
0.00
EV/EBITDA
-2.11
DCF Value
$1.01
FCF Yield
-28.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.3%
ROA
-50.2%
ROIC
-63.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-54.9M | $-44.9M | $-0.57 | — |
| FY 2025 | $0.00 | -Infinity% | $-180.9M | $-158.3M | $-1.94 | — |
| Q3 2025 | $0.00 | NaN% | $-45.6M | $-42.0M | $-0.53 | — |
| Q2 2025 | $0.00 | -Infinity% | $-41.3M | $-37.2M | $-0.44 | — |
| Q1 2025 | $0.00 | -Infinity% | $-39.0M | $-34.3M | $-0.40 | — |
| Q4 2024 | $0.00 | -Infinity% | $-39.0M | $-33.5M | $-0.40 | — |
| FY 2024 | $0.00 | -Infinity% | $-192.9M | $-168.4M | $-2.00 | — |
| Q3 2024 | $0.00 | -Infinity% | $-37.2M | $-31.2M | $-0.37 | — |
| Q2 2024 | $0.00 | -Infinity% | $-46.9M | $-40.5M | $-0.48 | — |
| Q1 2024 | $0.00 | -Infinity% | $-69.8M | $-63.2M | $-0.75 | — |
| Q4 2023 | $0.00 | -Infinity% | $-46.6M | $-39.2M | $-0.47 | — |
| FY 2023 | $0.00 | -Infinity% | $-164.2M | $-136.0M | $-1.63 | — |